Skip to main content

You are using an old and unsupported browser. Most core functionality will not work. Please upgrade to a supported browser - Google Chrome

Times are shown in your local time zone GMT

Agonising Mitofusin2 for the treatment of prostate cancer

Presentation Description

Institution: University of Adelaide, SAHMRI - South Australia, Australia

Mitochondria are dynamic organelles undergoing continuous fusion and fission events to meet various energetic and biosynthetic cellular demands. The morphology of mitochondria ranges from small, punctate and discrete mitochondria to elongated tubules with further fusion events facilitating the formation of large electronically continuous organelles. These events are regulated by numerous proteins including  Mitofusin2 (MFN2), an outer mitochondrial membrane fusion mediator. MFN2 mRNA is downregulated in prostate cancer tissue and its low expression is associated with decreased disease free patient survival. Therefore, we aim to evaluate the therapeutic efficacy of agonising MFN2 in prostate cancer. 


Doug A Brooks - Ian R D Johnson - Elizabeth H Collis - Zeyad D Nassar - Lisa M Butler -